Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma

NCT00310037 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00310037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00310037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
June 30, 2022
Enrollment
151 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma